🚀 VC round data is live in beta, check it out!
Ipsen Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ipsen and similar public comparables like Torrent Pharmaceuticals, Ascendis Pharma, Alteogen, Zhangzhou Pientzehuang and more.
Ipsen Overview
About Ipsen
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
Founded
1998
HQ
Employees
5.4K
Website
Sectors
Financials (LTM)
EV
$15B
Ipsen Financials
Ipsen reported last 12-month revenue of $4B and EBITDA of $2B.
In the same LTM period, Ipsen generated $4B in gross profit, $2B in EBITDA, and $610M in net income.
Revenue (LTM)
Ipsen P&L
In the most recent fiscal year, Ipsen reported revenue of $5B and EBITDA of $2B.
Ipsen expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4B | XXX | $5B | XXX | XXX | XXX |
| Gross Profit | $4B | XXX | $4B | XXX | XXX | XXX |
| Gross Margin | 82% | XXX | 81% | XXX | XXX | XXX |
| EBITDA | $2B | XXX | $2B | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 38% | XXX | XXX | XXX |
| EBIT Margin | 35% | XXX | 34% | XXX | XXX | XXX |
| Net Profit | $610M | XXX | $528M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 12% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ipsen Stock Performance
Ipsen has current market cap of $16B, and enterprise value of $15B.
Market Cap Evolution
Ipsen's stock price is $189.44.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15B | $16B | (0.9%) | XXX | XXX | XXX | $6.41 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIpsen Valuation Multiples
Ipsen trades at 3.3x EV/Revenue multiple, and 8.6x EV/EBITDA.
EV / Revenue (LTM)
Ipsen Financial Valuation Multiples
As of March 11, 2026, Ipsen has market cap of $16B and EV of $15B.
Equity research analysts estimate Ipsen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ipsen has a P/E ratio of 25.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16B | XXX | $16B | XXX | XXX | XXX |
| EV (current) | $15B | XXX | $15B | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 8.6x | XXX | 8.8x | XXX | XXX | XXX |
| EV/EBIT | 9.6x | XXX | 9.7x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | 4.1x | XXX | XXX | XXX |
| P/E | 25.6x | XXX | 29.5x | XXX | XXX | XXX |
| EV/FCF | 14.1x | XXX | 14.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ipsen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ipsen Margins & Growth Rates
Ipsen's revenue in the last 12 month grew by 8%.
Ipsen's revenue per employee in the last FY averaged $0.8M.
Ipsen's rule of 40 is 47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ipsen's rule of X is 60% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Ipsen Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 47% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 24% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 20% | XXX | 19% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ipsen Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Torrent Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascendis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Alteogen | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhangzhou Pientzehuang | XXX | XXX | XXX | XXX | XXX | XXX |
| Yunnan Baiyao Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ipsen M&A Activity
Ipsen acquired XXX companies to date.
Last acquisition by Ipsen was on XXXXXXXX, XXXXX. Ipsen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ipsen
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIpsen Investment Activity
Ipsen invested in XXX companies to date.
Ipsen made its latest investment on XXXXXXXX, XXXXX. Ipsen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ipsen
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ipsen
| When was Ipsen founded? | Ipsen was founded in 1998. |
| Where is Ipsen headquartered? | Ipsen is headquartered in France. |
| How many employees does Ipsen have? | As of today, Ipsen has over 5K employees. |
| Who is the CEO of Ipsen? | Ipsen's CEO is David Loew. |
| Is Ipsen publicly listed? | Yes, Ipsen is a public company listed on Euronext Paris. |
| What is the stock symbol of Ipsen? | Ipsen trades under IPN ticker. |
| When did Ipsen go public? | Ipsen went public in 2005. |
| Who are competitors of Ipsen? | Ipsen main competitors are Torrent Pharmaceuticals, Ascendis Pharma, Alteogen, Zhangzhou Pientzehuang. |
| What is the current market cap of Ipsen? | Ipsen's current market cap is $16B. |
| What is the current revenue of Ipsen? | Ipsen's last 12 months revenue is $4B. |
| What is the current revenue growth of Ipsen? | Ipsen revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Ipsen? | Current revenue multiple of Ipsen is 3.3x. |
| Is Ipsen profitable? | Yes, Ipsen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ipsen? | Ipsen's last 12 months EBITDA is $2B. |
| What is Ipsen's EBITDA margin? | Ipsen's last 12 months EBITDA margin is 39%. |
| What is the current EV/EBITDA multiple of Ipsen? | Current EBITDA multiple of Ipsen is 8.6x. |
| What is the current FCF of Ipsen? | Ipsen's last 12 months FCF is $1B. |
| What is Ipsen's FCF margin? | Ipsen's last 12 months FCF margin is 24%. |
| What is the current EV/FCF multiple of Ipsen? | Current FCF multiple of Ipsen is 14.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.